{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.","groups":[{"description":"Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W","id":"OG000","title":"Part A - Flat Dosing (AF)"},{"description":"Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W","id":"OG001","title":"Part A - Age/Weight-based Dosing (AW)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in part A","reportingStatus":"POSTED","timeFrame":"from first dose to 135 days post last dose (Up to approximately 11 months)","title":"Number of Participants With Serious Adverse Events (SAEs) - Part A","type":"PRIMARY","unitOfMeasure":"Participants"}